| Primary |
| Anaemia |
17.9% |
| Haemoglobin Decreased |
12.8% |
| Aortic Aneurysm Repair |
10.3% |
| Product Used For Unknown Indication |
10.3% |
| Transfusion-related Acute Lung Injury |
7.7% |
| Blood Product Transfusion |
5.1% |
| Haemorrhage |
5.1% |
| Ruptured Ectopic Pregnancy |
5.1% |
| Haematocrit Decreased |
2.6% |
| Haemorrhagic Anaemia |
2.6% |
| Hip Surgery |
2.6% |
| Hypopharyngeal Cancer |
2.6% |
| Operative Haemorrhage |
2.6% |
| Pharyngeal Cancer Stage Unspecified |
2.6% |
| Road Traffic Accident |
2.6% |
| Transfusion |
2.6% |
| Upper Gastrointestinal Haemorrhage |
2.6% |
| Urosepsis |
2.6% |
|
| Transfusion-related Acute Lung Injury |
31.9% |
| Transfusion Reaction |
14.9% |
| Laboratory Test Abnormal |
6.4% |
| Wheezing |
6.4% |
| Product Quality Issue |
4.3% |
| Transfusion-transmitted Infectious Disease |
4.3% |
| Vomiting |
4.3% |
| Circumstance Or Information Capable Of Leading To Medication Error |
2.1% |
| Hyperhidrosis |
2.1% |
| Hypoxia |
2.1% |
| Intercepted Drug Dispensing Error |
2.1% |
| Medication Error |
2.1% |
| Respiratory Failure |
2.1% |
| Resuscitation |
2.1% |
| Sepsis |
2.1% |
| Shock |
2.1% |
| Skin Lesion |
2.1% |
| Transfusion |
2.1% |
| Unevaluable Event |
2.1% |
| Urticaria |
2.1% |
|
| Secondary |
| Drug Use For Unknown Indication |
20.2% |
| Drug Therapy |
8.9% |
| Shock Haemorrhagic |
7.4% |
| Product Used For Unknown Indication |
6.8% |
| Nutritional Support |
6.4% |
| Pancytopenia |
6.0% |
| Haemorrhagic Disorder |
5.1% |
| Sedation |
4.7% |
| Pain |
4.0% |
| Cardiac Failure |
3.4% |
| Fluid Replacement |
3.4% |
| Intraoperative Care |
3.4% |
| Thrombosis Prophylaxis |
3.2% |
| Prophylaxis Against Gastrointestinal Ulcer |
3.0% |
| Aortic Aneurysm Repair |
2.6% |
| Infection |
2.6% |
| Blood Product Transfusion |
2.3% |
| Operative Haemorrhage |
2.3% |
| Restlessness |
2.3% |
| Allogenic Bone Marrow Transplantation Therapy |
1.9% |
|
| Renal Failure Acute |
25.0% |
| Transfusion-related Acute Lung Injury |
13.6% |
| Transmission Of An Infectious Agent Via A Medicinal Product |
11.4% |
| Hepatitis C |
8.0% |
| Hepatitis B Surface Antigen Positive |
5.7% |
| Thermal Burn |
4.5% |
| Toxic Epidermal Necrolysis |
4.5% |
| Htlv-1 Test Positive |
3.4% |
| Toothache |
3.4% |
| Transfusion Reaction |
3.4% |
| Hepatitis B |
2.3% |
| Hepatitis C Virus |
2.3% |
| Hepatitis Post Transfusion |
2.3% |
| Multi-organ Failure |
2.3% |
| Transfusion-related Circulatory Overload |
2.3% |
| Abdominal Pain |
1.1% |
| Anaemia |
1.1% |
| Anti-hbs Antibody Positive |
1.1% |
| Anxiety |
1.1% |
| Haemoglobin Decreased |
1.1% |
|
| Concomitant |
| Product Used For Unknown Indication |
33.3% |
| Drug Use For Unknown Indication |
14.1% |
| Prophylaxis |
8.2% |
| Coronary Artery Bypass |
7.1% |
| Multiple Myeloma |
5.3% |
| Pain |
3.5% |
| Anaemia |
3.2% |
| Hypertension |
3.1% |
| Myelodysplastic Syndrome |
3.0% |
| Premedication |
2.6% |
| Aortic Valve Replacement |
2.3% |
| Infection Prophylaxis |
2.2% |
| Catheterisation Cardiac |
1.9% |
| Nausea |
1.9% |
| Constipation |
1.6% |
| Anxiety |
1.4% |
| Aplastic Anaemia |
1.4% |
| Prophylaxis Against Graft Versus Host Disease |
1.4% |
| Iron Overload |
1.3% |
| Nuclear Magnetic Resonance Imaging |
1.3% |
|
| Injury |
11.3% |
| Pain |
10.2% |
| Unevaluable Event |
8.1% |
| Fear |
6.8% |
| Anhedonia |
6.3% |
| Renal Failure |
5.9% |
| White Blood Cell Count Decreased |
5.8% |
| Thrombocytopenia |
5.3% |
| Anxiety |
4.7% |
| Renal Impairment |
4.5% |
| Sepsis |
4.0% |
| Emotional Distress |
3.8% |
| Stress |
3.7% |
| Pneumonia |
3.0% |
| Depression |
3.0% |
| Renal Failure Acute |
2.9% |
| Multi-organ Failure |
2.9% |
| Death |
2.8% |
| Pyrexia |
2.7% |
| Weight Decreased |
2.3% |
|
| Interacting |
| Drug Use For Unknown Indication |
76.5% |
| Febrile Neutropenia |
5.9% |
| Fungal Infection |
5.9% |
| Haemorrhage |
5.9% |
| Pain |
5.9% |
|
| Pulmonary Oedema |
50.0% |
| Urticaria |
50.0% |
|
